A Phase 3 interventional study of Anidulafungin and Fluconazole in Invasive Candidiasis, sponsored by Pfizer. Completed at 61 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-30.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing anidulafungin in Candidemia — none open to participants now, none under way, none of them phase 3. Anidulafungin · Candidemia.
Among the 11 studies testing anidulafungin in Candidemia, this one is the 3rd largest by enrollment, is one of 5 that started in 2008, is one of 5 in phase 3, and was the 7th registered.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
Browse Candidemia studies →None of the 11 studies testing anidulafungin in Candidemia is open now. The open studies under Candidemia, anywhere →
Anidulafungin: first FDA approval 2006 (ERAXIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 63 across 44 interventional studies indexed under Candidemia.
Median enrollment 70 across the 11 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Candidemia by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 15 studies in Candidemia by Pfizer, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 6 that started in 2008, is one of 7 in phase 3, and was the 6th registered.
Pfizer’s Candidemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing anidulafungin in Candidemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Candidemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
This study's enrollment of 216 is above the median of 63 across 44 interventional studies indexed under Candidemia.
Browse Candidemia studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Candidemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Candidiasis, Invasive. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ICU patients with a diagnosis of documented candidemia or invasive candidiasis and belonging to one or more of the following specific populations:
Exclusion Criteria:
Patients with poor venous access that would preclude IV drug delivery or multiple blood draws.
Option to treat with oral azole therapy following treatment with anidulafungin
Drug: Anidulafungin · Drug: Fluconazole · Drug: Voriconazole
Anidulafungin Intravenous Administration
Oral Administration of Fluconazole
Oral Administration of Voriconazole
Percentage of Participants With Global Treatment Response Success at End of Treatment
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
Time frame: End of Treatment (Day 14 to Day 56)
Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
Time frame: EOIVT (Day 10 up to Day 42)
Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
Time frame: 2 weeks after End of Treatment (Day 14 + 14 up to Day 56 + 14)
Percentage of Participants With Global Response Success 6 Weeks After End of Treatment
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
Time frame: 6 weeks after End of Treatment (Day 14 + 42 up to Day 56 + 42)
Time to First Negative Blood Culture
Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication.
Time frame: Day 1 up to Day 42
Day 90 Survival
Percentage of participants known or assumed to be alive on Day 90.
Time frame: Day 90
Time to Successful Intensive Care Unit (ICU) Discharge
Time from start of study medication to successful ICU discharge (by end of treatment \[EOT\]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT.
Time frame: Day 1 up to Day 56
Adult specific participants were recruited from intensive care unit (ICU) populations.
| Milestone | Anidulafungin |
|---|---|
| Started | 216 |
| Completed | 73 |
| Not completed | 143 |
| Withdrew: Death | 65 |
| Withdrew: Adverse event | 13 |
| Withdrew: Insufficient clinical response | 1 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Other | 8 |
| Withdrew: Did not meet entrance criteria | 27 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Protocol violation | 15 |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
| percentage of participants | Anidulafungin |
|---|---|
| Percentage of Participants With Global Treatment Response Success at End of Treatment | 69.5 (61.6 to 76.6) |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
| percentage of participants | Anidulafungin |
|---|---|
| Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT) | 70.7 (62.9 to 77.7) |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
| percentage of participants | Anidulafungin |
|---|---|
| Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment | 60.2 (51.1 to 68.7) |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).
| percentage of participants | Anidulafungin |
|---|---|
| Percentage of Participants With Global Response Success 6 Weeks After End of Treatment | 50.5 (40.7 to 60.2) |
Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication.
| days | Anidulafungin |
|---|---|
| Time to First Negative Blood Culture | 3.7 (3.0 to 4.3) |
Percentage of participants known or assumed to be alive on Day 90.
| percentage of participants | Anidulafungin |
|---|---|
| Day 90 Survival | 54.1 (46.3 to 61.8) |
Time from start of study medication to successful ICU discharge (by end of treatment \[EOT\]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT.
| days | Anidulafungin |
|---|---|
| Time to Successful Intensive Care Unit (ICU) Discharge | 16.2 (13.3 to 19.1) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anidulafungin | — | 107/216 (49.5%) | 78/216 (36.1%) |
| Event | Anidulafungin |
|---|---|
| Septic shockInfections and infestations | 21/216 |
| Multi-organ failureGeneral disorders | 12/216 |
| Cardiac arrestCardiac disorders | 10/216 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 9/216 |
| SepsisInfections and infestations | 6/216 |
| Renal failureRenal and urinary disorders | 6/216 |
| Cardiac failureCardiac disorders | 5/216 |
| Cardio-respiratory arrestCardiac disorders | 5/216 |
| Abdominal operationSurgical and medical procedures | 5/216 |
| PneumoniaInfections and infestations | 3/216 |
| Event | Anidulafungin |
|---|---|
| DiarrhoeaGastrointestinal disorders | 20/216 |
| AnaemiaBlood and lymphatic system disorders | 16/216 |
| HypertensionVascular disorders | 16/216 |
| HypotensionVascular disorders | 15/216 |
| NauseaGastrointestinal disorders | 12/216 |
| PyrexiaGeneral disorders | 12/216 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/216 |
| Atrial fibrillationCardiac disorders | 11/216 |
| TachycardiaCardiac disorders | 11/216 |
| Age, Customized(participants) | Anidulafungin |
|---|---|
| <18 years | 0 |
| 18 to 44 years | 27 |
| 45 to 64 years | 89 |
| ≥ 65 years | 100 |
| Sex: Female, Male(Participants) | Anidulafungin |
|---|---|
| Female | 85 |
| Male | 131 |
The record gives a start of Jul 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anidulafungin · Fluconazole · Voriconazole